Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

The Finviz API:   Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now
Market News Market Pulse Stocks News ETF News Crypto News

C4 Therapeutics, Inc.

Contributing Author

Recent Articles by C4 Therapeutics, Inc.

Sep-25
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting CCCC GlobeNewswire
Sep-03
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting CCCC GlobeNewswire
Aug-11
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights CCCC +6.91% GlobeNewswire
Aug-10
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC GlobeNewswire
Jun-11
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population CCCC GlobeNewswire
May-20
C4 Therapeutics to Participate in Upcoming Conferences CCCC +5.47% GlobeNewswire
May-18
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC -9.55% GlobeNewswire
May-12
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Apr-09
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) CCCC GlobeNewswire
Mar-25
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma CCCC +7.60% GlobeNewswire
Mar-09
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC +18.09% CCCC -13.09% GlobeNewswire
Feb-26
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Feb-23
C4 Therapeutics to Participate in Upcoming March Conferences CCCC +6.48% GlobeNewswire
Feb-23
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma CCCC +6.48% GlobeNewswire
Feb-09
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC GlobeNewswire
Feb-04
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 CCCC -5.97% GlobeNewswire
Jan-26
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CCCC GlobeNewswire
Jan-14
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways CCCC GlobeNewswire
Nov-25
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference CCCC GlobeNewswire
Nov-06
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights CCCC GlobeNewswire
Oct-16
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering CCCC +11.71% GlobeNewswire
Oct-01
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma CCCC GlobeNewswire
Sep-20
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting CCCC GlobeNewswire
Sep-04
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration CCCC GlobeNewswire
Sep-03
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting CCCC GlobeNewswire
Aug-07
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights CCCC +31.63% GlobeNewswire
May-07
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights CCCC +6.38% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)